Orforglipron
orforglipron
FILED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Peak Sales Est$15000M
Formulations[]
Mechanism: Oral GLP-1 agonist
Expert: Small molecule oral GLP-1 receptor agonist with enhanced oral bioavailability for metabolic disease.
Everyday: A pill that mimics a gut hormone to reduce appetite and help with weight loss and blood sugar.
Targets: ["GLP-1"]
Programs (2)
| Indication | Stage | Key Study | Regional Status |
|---|
| Obesity | PHASE3 | ATTAIN-1/2/3 | [{"stage":"PHASE3","region":"US"}] |
| T2D | FILED | ACHIEVE-1/2/3/4/5 | [{"stage":"FILED","region":"US","filing_date":"2025-06-15"},{"stage":"FILED","re |
Upcoming Catalysts (3)
Orforglipron - Obesity - FDA Approval
March 2026
Orforglipron - Obesity/T2D - EMA Approval
H2 2026
Orforglipron - Obesity - FDA Approval (Royalty)
Late 2026
Notes
PDUFA March 2026. First oral small molecule GLP-1. Priced at $150/month.
Data from Supabase · Updated 2026-03-24